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ABSTRACT
Background Systemic sclerosis (SSc)-overlap syndromes
are a very heterogeneous and remarkable subgroup of
SSc-patients, who present at least two connective tissue
diseases (CTD) at the same time, usually with a speciﬁc
autoantibody status.
Objectives To determine whether patients, classiﬁed
as overlap syndromes, show a disease course different
from patients with limited SSc (lcSSc) or diffuse
cutaneous SSc (dcSSc).
Methods The data of 3240 prospectively included
patients, registered in the database of the German
Network for Systemic Scleroderma and followed between
2003 and 2013, were analysed.
Results Among 3240 registered patients, 10% were
diagnosed as SSc-overlap syndrome. Of these, 82.5%
were female. SSc-overlap patients had a mean age of 48
±1.2 years and carried signiﬁcantly more often ‘other
antibodies’ (68.0%; p<0.0001), including anti-U1RNP,
-PmScl, -Ro, -La, as well as anti-Jo-1 and
-Ku antibodies.
These patients developed musculoskeletal involvement
earlier and more frequently (62.5%) than patients
diagnosed as lcSSc (32.2%) or dcSSc (43.3%)
(p<0.0001). The onset of lung ﬁbrosis and heart
involvement in SSc-overlap patients was signiﬁcantly
earlier than in patients with lcSSc and occurred later
than in patients with dcSSc. Oesophagus, kidney and PH
progression was similar to lcSSc patients, whereas dcSSc
patients had a signiﬁcantly earlier onset.
Conclusions These data support the concept that
SSc-overlap syndromes should be regarded as a separate
SSc subset, distinct from lcSSc and dcSSc, due to a
different progression of the disease, different
proportional distribution of speciﬁc autoantibodies, and
of different organ involvement.
INTRODUCTION
Systemic sclerosis (SSc) is a heterogeneous, multi-
system, chronic disorder, leading to ﬁbrosis of the
skin and many internal organs. To classify patients
with established disease, the American College of
Rheumatology published in 1980 preliminary cri-
teria.1 Currently a subclassiﬁcation developed by
LeRoy et al, this is the most widely used classiﬁca-
tion system for limited and diffuse SSc in clinical
practice,2 and is the basis for many registries world-
wide.3 In these registries, it became apparent that
in a sizeable number of patients, symptoms of SSc
occur in combination with those of other connect-
ive tissue diseases (CTD),4–10 also described by
some authors as SSc-overlap syndrome.4 11–13 Up
to now, no ﬁrm classiﬁcation criteria for
SSc-overlap syndromes are established, but it is gen-
erally considered when musculoskeletal involve-
ment (myositis, arthritis) or clinical signs of other
rheumatic diseases are substantially greater than
usually found in SSc patients.12
Clinical features of overlap syndrome patients
are very heterogeneous, and epidemiological
studies report divergent frequencies of overlap sub-
groups as well as of organ manifestations.11 14 15
Musculoskeletal involvement, including joints,
tendons and muscles, is the most frequent clinical
feature, highlighting the difference to other SSc
forms. Inﬂammatory joint involvement is reported
to be the second most frequent manifestation in
patients with musculoskeletal involvement and
overlap syndromes. These patients are often identi-
ﬁed by typical clinical symptoms (usually limited
skin involvement) together with high titres of antic-
yclic citrullinated peptides (CCP/ACPA) and/or
higher rheumatoid factors (RF).16 17
All known classiﬁcation criteria for overlap syn-
dromes include autoantibodies, which are helpful
to separate them from other subsets.18–20 PmScl-
and anti-U1RNP-antibodies are known to be the
most common autoantibodies in patients with
overlap syndromes.21–24
Pakozdi et al reported recently, that 20% of the
patients attending the Centre for Rheumatology at
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the Royal Free Hospital had overlapping features with other
rheumatologic diseases, such as polymyositis/dermatomyositis
(43%), systemic lupus erythematosus (SLE) (8%), Sjögren’s syn-
drome (17%) and rheumatoid arthritis (32%).12
It has been always debated whether patients suffering from
overlap syndromes should be regarded as a separate entity, or
should be included, depending on their skin involvement, in the
two main groups of limited (lcSSc) and diffuse SSc (dcSSc)
patients.
In this prospective study, it could be shown for the ﬁrst time
that SSc-overlap syndromes should be viewed as a distinct SSc
subset.
MATERIALS AND METHODS
This study involves 3240 patients, registered in the database of
the German Network for Systemic Scleroderma (DNSS). The
network combines different subspecialties consisting of rheuma-
tologists, dermatologists, pulmonologists and nephrologists from
altogether more than 40 clinical centres. The Ethics Committee
of the coordinating centre, that is, the Cologne University
Hospital, gave a positive vote on the patient information and
consent form for the registry. On the basis of this document, all
participating centres received the approval of their local ethics
committees prior to registering patients.
Patient data, including information about gender, age, auto-
antibodies, SSc subsets, symptoms and signs, organ involvement,
modiﬁed Rodnan Skin Score (mRSS) as well as treatments, were
recorded on a prospective basis in a database started in 200325–27
with a mean follow-up time of 9.5±0.2 years (from the time of
SSc onset till the last follow-up visit). A signiﬁcant number of
these patients were classiﬁed according to the criteria of LeRoy
et al2 as having lcSSc or dcSSc. Additionally, a smaller but still
considerable number of patients, did not fulﬁl these criteria, but
were registered to follow-up their course of disease. Data of the
ﬁrst Raynaud phenomenon (RP) onset, as well as data of
non-RP onset of skin and organ involvement were recorded.
Due to the lack of satisfying classiﬁcation criteria for patients
with different forms of overlap syndromes, all patients with
more than one CTD were classiﬁed as SSc-overlap syndrome in
general, including symptoms and signs, autoantibodies and
organ manifestations in detail. This information was used to
characterise patients with SSc-overlap syndromes.
SSc subsets
Patients with overlap syndromes were deﬁned as a disease,
occurring with clinical features of SSc, according to the ACR
criteria, or main SSc-associated symptoms, simultaneously with
those typical for other rheumatic diseases.4 These patients were
often positive for anti-PmScl, -U1RNP, -Jo-1, -Ku, -Ro or –La
autoantibodies. Patients with a mixed connective tissue disease
(MCTD) were also included in SSc-overlap syndromes, as
MCTD combines features of SLE, SSc and myositis, together
with the presence of anti-U1RNP-antibodies.
Patients suffering from dcSSc were characterised by a progres-
sive course of disease with an early onset of RP, usually within
1 year of onset of skin changes. They were deﬁned by rapid skin
involvement of the trunk, face, proximal and distal extremities
and being frequently associated with antitopoisomerase (ATA)
antibodies.2
LcSSc was deﬁned by skin thickening of the extremities distal
to the knee and elbow joints, facial skin and occurrence of RP,
which usually appeared many years prior to skin involvement.
These patients are often positive for anticentromer-antibodies
(ACA).2
Patients with undifferentiated SSc were deﬁned as positive RP
together with at least one further feature of SSc (typical nailfold
capillary alterations, puffy ﬁngers, pulmonary hypertension
(PH)) and/or detectable SSc-speciﬁc autoantibodies without ful-
ﬁlling the ACR criteria for SSc.28
Patients with sclerosis sine scleroderma were deﬁned by posi-
tive RP, no skin alterations, PAH, cardiac, pulmonary and gastro-
intestinal involvement.29
Within this study, we focused on patients suffering from
lcSSc, dcSSc and SSc-overlap syndromes.
Antinuclear autoantibodies (ANAs)
The antibody measurement was performed in respective labora-
tories of the participating centres. Serum was routinely analysed
in all registered SSc patients at the ﬁrst visit and repeated as
needed. Autoantibodies were subdivided into SSc-speciﬁc (ACA,
ATA, anti-PmScl, -U1RNP, -Jo1, -Ku antibodies) and SSc non-
speciﬁc autoantibodies (anti-Ro and -La antibodies). Missing
data were less than 10%.
Organ involvement
RP was deﬁned by recurrent vasospasms of small digital arter-
ioles/arteries at ﬁngers and/or toes, usually triggered by cold
environment. We deﬁned the age of RP onset as the age, at
which the RP ﬁrst appeared.25
The ﬁrst non-RP onset of organ involvement has been consid-
ered as the timepoint of ﬁrst skin or organ manifestation. The
onset of skin involvement has been set as onset of SSc.
Skin involvement was evaluated using the modiﬁed Rodnan
Skin Score (mRSS), which assesses the skin hardening/thickness
by manual palpation of 17 body areas on a scale of 0 to 3.
Pulmonary manifestation includes pulmonary interstitial
ﬁbrosis and/or isolated PH. Isolated pulmonary hypertension
was deﬁned as clinical evidence of right-heart failure and/or
increased mean pulmonary arterial pressure (PAPm>25 mm Hg
at rest or PAP>30 mm Hg during exercise), determined by
right-heart catheterisation. Echocardiography was used to iden-
tify likely PAH (estimated RVSP>40 mm Hg).
Pulmonary interstitial ﬁbrosis was established when bilateral
basal ﬁbrosis occurred, conﬁrmed by chest X-ray and/or high-
resolution CT scan together with restrictive pulmonary abnor-
malities on pulmonary function tests (TLC <80%), were found.
We deﬁned a normal diffusing capacity of lung for carbon mon-
oxide (DLCO) level, when it was >75%, and a low level, when
it was less than 75%.
Gastrointestinal involvement was deﬁned as gastrointestinal
motility disturbance, dysphagia, nausea, malabsorption,
oesophageal stenosis, gastro-oesophageal reﬂux or intestinal
pseudo-obstruction.
Kidney involvement was deﬁned as the presence of renal
insufﬁciency encompassing renal insufﬁciency due to acute renal
crisis (creatinine clearance age-related less than 80 mL/min). The
diagnosis of proteinuria was fulﬁlled in cases of albuminuria
>=30 mg/24 h or >=20 mg/L; proteinuria >=300 mg/24 h or
>=200 mg/L.
Cardiac disease was deﬁned by heart palpitation, conduction
disturbance and/or diastolic dysfunction.
Skeletal muscle disease was deﬁned as proximal muscle weak-
ness and/or atrophy associated with elevated serum muscle
enzyme (creatine phosphokinase, CK) levels and/or articular
involvement.25 The articular involvement included synovitis
with swelling, with or without tenderness to palpation in one or
more than one joint. The questionnaire also asked for any kind
of joint contractures or tendon friction rubs.
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Sicca syndrome was characterised by reduced glandular func-
tion, usually causing a dry mouth and dry eyes, while involve-
ment of the masticatory organ was characterised by
microstomia, deﬁned as obvious decreased mouth opening
clearly detected by the investigators due to the disease and/or
ﬁbrosis of the lingual frenulum.
The recommendations for follow up visits and investigations
(echocardiography, electrocardiogram, lung function test, etc)
are at least once per year.
Statistics
Differences between the SSc subsets were investigated, using χ2
test for categorical variables and t tests for continuous para-
meters. To compare the disease progression in the three main
subsets Kaplan–Meier analysis with log rank tests was per-
formed. The starting point of the Kaplan–Meier curves was set
as SSc onset, which we deﬁned as the time of ﬁrst non-RP mani-
festation (onset of skin involvement). The onset of different
organ involvements is illustrated within the course of the
disease according to our registered follow-up visits.
Additionally, univariate and multiple logistic regression ana-
lysis were used to assess the impact of SSc subsets, autoantibody
status, age and gender on organ involvement. OR and the corre-
sponding 95% CI are reported. To investigate the development
of DLCO over regular follow-up time, mixed model analysis
with backward selection was applied. Time since SSc onset,
group membership and their interaction were included as ﬁx
factors, and patient ID as a random effect. In order to guard
against type I error inﬂation due to multiple testing, only
p values below 0.001 were considered statistically signiﬁcant.
Statistical analysis was done with PASW Statistics V.18.0
(Chicago: SPSS). Missing data were less than 15% for organ
manifestations and clinical signs. Missing data for autoantibodies
are included within table 2 (less than 10%).
RESULTS
Patient characteristics of all SSc subsets
Between the years 2003 and 2012, a total of 3240 patients with
SSc had been registered in the DNSS database. Among all regis-
tered patients, 49.3% were diagnosed as lcSSc and 30.8% with
dcSSc, 10.0% with an overlap syndrome, 7.7% with undifferen-
tiated scleroderma, 0.7% with sclerosis sine scleroderma, and
1.4% patients were categorised as others. Within all registered
patients, 81.5% were female; 87.5% were positive for ANA,
33.7% had anticentromere antibodies, and 26.4% were antito-
poisomerase antibody (ATA) positive, while the remaining
patients had other antibody speciﬁcities (32.5%).
Of all registered patients (ﬁrst visit), 13.3% had PH, 36.5%
lung ﬁbrosis, 55.1% suffered from gastrointestinal involvement,
9.9% had kidney involvement, 12.5% suffered from heart
involvement, 39.1% from musculoskeletal involvement and
37.5% from sicca symptoms.
The mean time between the onset of SSc and the ﬁrst visit/
registration within our database was for all SSc patients
(n=2522) 7.6±0.2 years (SSc diagnosis to ﬁrst visit), for lcSSc
patients (n=1236) 8.3±0.2 years (SSc diagnosis to ﬁrst visit),
Table 1 Frequencies and p values (χ2 test) of organ manifestations and current symptoms in patients with overlap syndromes, compared to
patients with limited systemic sclerosis/diffuse cutaneous SSc (lcSSc/dcSSc)
SSc subsets p Values
Overlap s. (n=325) lcSSc (n=1598) dcSSc (n=997) Overlap versus lcSSc Overlap versus dcSSc
Female 82.5 85.9 73.1 0.122 0.001
Male 17.5 14.1 26.8
Positive family history 23.1 15.9 15.0 0.039 0.029
Age (mean±SD) 48±1.2 52.8±0.5 48.2±0.6 0.0001 0.847
Erythrocyte sedimentation rate (mean±SD) 23±1.2 17.9±0.4 23.4±0.7 0.0001 0.734
DLCO (mean±SD) 70.5±1.5 73.5±0.7 65.3±0.9 0.064 0.005
Modified Rodnan Skin Score (mean±SD) 6.8±0.4 7.4±0.2 15.8±0.3 0.191 0.0001
Organ involvement
Pulmonary hypertension 10.8 12.3 18.2 0.402 0.003
Lung fibrosis 35.7 24.9 61.2 0.0001 0.0001
Oesophagus 52.0 56.2 60.8 0.065 0.013
Kidney 6.8 8.3 14.3 0.318 0.0001
Heart 13.8 9.6 18.3 0.046 0.104
Musculoskeletal system 62.5 32.2 43.3 0.0001 0.0001
Sicca symptoms 40.0 39.5 33.8 0.703 0.049
Current clinical signs at first visit
Digital ulcers 18.2 23.3 33.3 0.034 0.0001
Synovitis 22.8 11.8 14.7 0.0001 0.004
Dermatogenous contractures 20.6 19.5 35.2 0.818 0.0001
Tendon friction rubs 8.0 5.4 10.4 0.090 0.198
Elevated creatine phosphokinase levels 17.8 6.3 10.5 0.0001 0.001
Muscle weakness 36.9 20.5 29.7 0.0001 0.032
Muscle atrophy 19.7 9.3 17.1 0.0001 0.453
Dysphagia 51.4 56.9 60.3 0.023 0.001
Renal failure 8.3 10.1 13.9 0.308 0.005
Proteinuria 8.0 6.4 11.0 0.330 0.114
DLCO, diffusing capacity of lung for carbon monoxide; SD, standard deviation.
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for dcSSc patients (n=857) 7.3±0.3 years (SSc diagnosis to ﬁrst
visit), and for overlap patients (n=238) 7.1±0.5 years (SSc diag-
nosis to ﬁrst visit).
The mean follow-up time between the SSc diagnosis and the
last follow-up visit registered in the DNSS was 9.5±0.2 years
for all SSc patients (n=2539), 10.1±0.2 years for lcSSc patients
(n=1244), 9.2±0.3 years for dcSSc patients (n=862) and 9.6
±0.6 years for SSc-overlap syndromes (n=241).
Overlap syndromes
Within the group of patients with overlap syndromes (n=325),
82.5% (268/325) were women and had a mean age at time of
SSc onset of 48±1.2 years (n=323) (table 1); 15.4% of these
patients were ACA positive, 13.2% ATA positive and 68.0%
carried other antibodies (compared to lcSSc (26.7%) and dcSSc
patients (31.1%); (p<0.0001)). These other antibodies con-
sisted of anti-U1RNP (33.0%), -Ro (24.4%), -PmScl (16.7%),
-La (10.9%), -Ku (3.6%), -Jo1 antibodies (4.1%) and others
(6.3%) (table 2).
During follow-up, of all 325 patients, more than 92.0%
maintained their initial diagnosis. Patients with SSc-overlap syn-
dromes tended to have more often a positive family history for
rheumatological disorders compared to lcSSc and dcSSc
patients, and were signiﬁcantly more frequently treated with
corticosteroids (60.6% vs 27.3% (lcSSc) and 44.3% (dcSSc);
p<0.0001) and immunosuppressive agents (58.8% vs 21.0%
(lcSSc) and 41.6% (dcSSc); p<0.0001) than other SSc subsets,
as published in 2009.26 Additionally, this speciﬁc subset also
had a signiﬁcantly lower mRSS compared to dcSSc patients (6.8
±0.4 vs 15.8±0.3; p<0.0001), but a very similar mean mRSS
to lcSSc patients (7.4±0.2) (table 1). Following the criteria of
LeRoy for limited and diffuse extension of skin thickening, we
had 76.0% of patients with a limited extension and 14.8% with
a diffuse form of skin thickening. Signiﬁcantly more female
SSc-overlap patients had a limited skin involvement (87.8% vs
63.3%; p<0.0001), while signiﬁcant more male patients suf-
fered from a diffuse skin involvement (36.7% vs 12.2%;
p<0.0001). No signiﬁcant abnormalities for organ manifesta-
tions/clinical signs or antibody distribution have been found.
Interestingly, signiﬁcantly less patients with overlap syndromes
suffered from digital ulcers (18.2% vs 33.3%; p<0.0001) (see
online supplementary table S1).
Musculoskeletal involvement
Patients with overlap syndrome developed signiﬁcantly earlier
and more often musculoskeletal involvement, followed by
patients with diffuse and limited SSc (data shown in table 1 and
ﬁgure 1A). Musculoskeletal manifestation included muscle
weakness (36.9%), synovitis (22.8%), contractures (2.6%),
muscle atrophy (19.7%) and elevated CK levels (17.8%).
Logistic regression analysis revealed, that overlap patients had
threefold the risk of developing musculoskeletal involvement,
compared to patients with lcSSc (OR 3.2; p<0.001; 95%-CI
2.5 to 4.2), and double the risk compared to dcSSc patients
(OR 2.2; p<0.001; 95%-CI 1. 6 to 2.9).
We also found that the course of initially elevated CK serum
levels decreased substantially over time, especially in overlap
and dcSSc patients (ﬁgure 3A).
In a subgroup of patients classiﬁed as overlap syndrome with
myositis and CK elevation (44/325), we determined the fre-
quency of gender distribution (70.5% women, 29.5% men), as
well as clinical features; 59.1% had oesophageal involvement,
38.6% of patients had lung ﬁbrosis, and 34.1% suffered from
cardiac involvement, while less than 15.0% had kidney failure
or signs for PH. Most of the patients selected for myositis and
CK elevation were PmScl positive (22.7%) followed by 9.1%
anti-U1RNP antibodies, 6.8% ATA antibodies and 4.5% ACA,
Ku- and Jo1-antibodies.
Cardiopulmonary involvement
Lung ﬁbrosis and heart involvement was diagnosed earliest in
patients with dcSSc, followed by SSc-overlap and lcSSc patients
(log rank test p<0.0001); patients with SSc-overlap syndromes
resulted in a clear intermediate position between patients suffer-
ing from lcSSc and dcSSc (ﬁgures 1B and 2A).
Logistic regression analysis revealed that patients with overlap
syndromes had a higher risk of developing lung ﬁbrosis com-
pared to lcSSc patients (OR 1.6; p<0.001; 95%-CI 1.2 to 2.1),
and a reduced risk compared to dcSSc patients (OR 0.4;
p<0.001; 95%-CI 0.3 to 0.5). They also had a lower risk of
developing lung ﬁbrosis when they had a high DLCO-level (OR
0.9; p<0.001; 95%-CI 0.9 to 1.0). The analysis of DLCO
within regular follow-up visits showed no signiﬁcant interaction,
for example, the decrease in DLCO over time does not differ
between group memberships. However, there was an overall
Table 2 Detailed autoantibody status of patients with overlap syndromes, compared to patients with lcSSc/dcSSc
SSc subsets p Values
Overlap
s. (n=325) lcSSc (n=1598) dcSSc (n=997) Overlap versus lcSSc Overlap versus dcSSc
Autoantibodies % md % md % md
ANAs positive 92.0 3.1 87.9 4.1 89.1 4.1 0.050 0.240
ACA positive 15.4 5.2 53.8 7.6 8.4 8.9 0.0001 0.001
ATA positive 13.2 4.9 16.0 7.9 52.4 8.0 0.155 0.0001
Other Abs 68.0 4.3 26.7 6.9 31.1 7.2 0.0001 0.0001
Other Abs than ACA & ATA, including (n=221) (n=426) (n=310)
PmScl 16.7 5.9 2.6 0.0001 0.0001
anti-U1RNP 33.0 5.4 3.9 0.0001 0.0001
Jo-1 4.1 0.5 1.9 0.001 0.183
Ku 3.6 0.5 2.3 0.006 0.601
Ro 24.4 23.5 27.7 0.770 0.484
La 10.9 10.6 14.2 0.894 0.294
md, missing data; missing data were less than 10%.
Abs, antibodies; ACA, anticentromer antibodies; ATA, antitopoisomerase antibodies; ANAs, antinuclear autoantibodies.
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signiﬁcant difference in DLCO between groups (p<0.001) and
between the years since SSc onset (p<0.001). A posthoc test
revealed additionally a signiﬁcant difference between years 1
and 5, again the course of the curve of overlap patients was
running between dcSSc and lcSSc patients (ﬁgure 3B).
Other organ manifestations
Disease progression, as determined by the onset of PH,
oesophagus and kidney involvement of SSc-overlap patients,
was similar to lcSSc patients. There was also no signiﬁcant dif-
ference in patients developing gastrointestinal involvement,
Figure 1 Kaplan–Meier analysis of the onset of (A) musculoskeletal involvement and (B) lung ﬁbrosis in lcSSc, dcSSc and SSc-overlap syndromes.
Events (deﬁned as onset of musculoskeletal involvement or lung ﬁbrosis) correspond to step-downs, while censored observations (deﬁned as last
follow up visit) are identiﬁed as ticks. The plot shows a signiﬁcant difference (p<0.0001) between the survival curves of lcSSc, dcSSc and overlap
syndrome patients.
Figure 2 Kaplan–Meier analysis of the onset of (A) heart involvement and (B) PH in lcSSc, dcSSc and SSc-overlap syndromes. Events (deﬁned as
onset of heart involvement or PH) correspond to step-downs while censored observations (deﬁned as last follow-up visit) are identiﬁed as ticks. The
plot shows a signiﬁcant difference (p<0.0001) between the survival curves of lcSSc, dcSSc and overlap syndrome patients.
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depending on their subset, gender and autoantibody status
(table 1 and online supplementary table S1, ﬁgure 2B).
Autoantibody status
Detailed characterisation of overlap patients depending on their
autoantibody status revealed that patients with
anti-U1RNP-antibodies were signiﬁcantly younger at RP onset,
compared with PmScl-positive patients (36.2±1.8 years vs 44.6
±2.3 years; p<0.008) and tended to be younger at onset of skin
manifestations (39.3±2.0 years vs 5.3±2.4 years). The interval
between RP onset and skin onset was shortest for patients with
Ku antibodies (0.7±0.7 years), followed by Jo1 (1.6±0.9 years),
PmScl (2.0±0.6 years), ATA (2.1±0.8 years), Ro (5.0
±1.3 years), La (5.2±2.5 years), anti-U1RNP (6.7±1.4 years),
followed by ACA-positive patients with 11.2±2.4 years.
DISCUSSION
SSc is a heterogeneous disease and includes subsets which are
characterised by the extension of skin involvement and circulat-
ing autoantibodies. For many years it has been observed, that
not all SSc patients ﬁt into the categories deﬁned by LeRoy
et al2 A considerable number of patients present with symptoms
and signs of SSc together with clinical features of other CTDs.5
Of the 3240 patients registered in the DNSS, 10.0% were
categorised as overlap syndrome. This frequency is in agreement
with other reported data, ranging between 10.0% and
38.0%.4 14 30–32 Our study presents one of the largest studies,
characterising patients with overlap syndromes in direct com-
parison with the two main SSc subsets, and our data indicate
that overlap patients clearly differ from lcSSc and dcSSc.
Totally, 62.5% of the overlap patients in this study had mus-
culoskeletal manifestations, which conﬁrms previously published
data of Balbir–Gurman et al, who reported myositis in 47.5%
of their 40 overlap patients, and Troyanov et al, who reported
SSc-myositis overlaps in 42.6% of their cases.33
In this registry, patients with SSc/myositis, who suffered from
muscle weakness together with elevated CK serum levels, 59.1%
had oesophageal involvement, 38.6% of patients had lung ﬁbro-
sis, 34.1% suffered from cardiac involvement, while less than
15.0% had kidney failure or signs for PH. These frequencies are
lower than in the study of Balbir–Gurman who reported higher
frequencies of occurrence, but the same trend in the order of
frequencies; 84.2% of patients with SSc-myositis had gastro-
intestinal involvement, 66.4% interstitial lung disease, and
26.3% cardiomyopathy or PH. Most of the patients showing
myositis and CK elevation were PmScl positive (22.7%), fol-
lowed by 9.1% anti-U1RNP antibodies, 7.0% ATA antibodies
and 4.5% ACA, anti-Ku and -Jo1 antibodies. Compared to these
data, other groups reported a higher frequency of ATA anti-
bodies.4 The frequency of elevated CK serum levels decreased
within the course of follow-up visits over a period of 9 years,
which could indicate that myositis responds to treatment.34 As
expected, signiﬁcantly more SSc-overlap patients have been put
on immunosuppressive treatment compared to lcSSc and/or
dcSSc patients, conﬁrming previously published data.26
We found signiﬁcantly more overlap patients with joint
involvement compared to lcSSc and dcSSc patients (p<0.0001),
but with no signiﬁcant difference in the frequency of RF positiv-
ity, although the presence of RF and the association with
rheumatoid arthritis of SSc patients have been previously dis-
cussed controversially.35
Regarding the onset of lung ﬁbrosis and heart involvement,
patients with SSc-overlap syndromes had an intermediate rate of
disease progression in between lcSSc and dcSSc. This observa-
tion is further supported by the DLCO levels following a similar
course. Overlap patients, in general, had signiﬁcantly less fre-
quent PH and kidney involvement than dcSSc patients. The
direct comparison between the three major SSc subsets, using
Kaplan–Meier curves, visualised that the trend of the
SSc-overlap curve was clearly between the curves standing for
lcSSc and dcSSc patients (ﬁgures 1 and 2).
Figure 3 Course of (A) the percentage of patients with elevated CK serum levels and (B) mean DLCO levels across all follow-up visits per year for
the three main SSc subsets.
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Additionally, patients with SSc-overlap syndromes were sig-
niﬁcantly younger (48±1.2 years) than patients with lcSSc, con-
ﬁrming the data of Garamaschi et al (48.5±13.3 years) and
developed less frequently digital ulcers, resulting in signiﬁcant
differences, when compared with dcSSc patients.
Furthermore, the data of this study are in good agreement
with Mierau et al and Hasegawa et al, who found that
anti-U1RNP antibodies were associated with a younger age of
disease onset when using a multiple regression analysis.27 36
However, Koschik et al reported that in their patient cohort,
patients with PmScl-antibodies were signiﬁcantly younger than
those without PmScl-antibodies.32 These patients developed
most frequently musculoskeletal involvement, including muscle
weakness and synovitis, but in contrast with other studies, less
lung ﬁbrosis.37 Our study, however, did not allow analysing,
whether symptoms and signs of other rheumatic diseases
appeared prior or after ﬁrst SSc features, but Caramaschi et al
reported, that 40.5% of their patients were diagnosed with an
additional autoimmune disease prior and 38.1% after SSc
diagnosis.30
In summary, we could demonstrate that patients with overlap
syndromes differ from lcSSc and dcSSc regarding lung ﬁbrosis
and heart involvement, and that musculoskeletal involvement is
clearly the most frequent organ manifestation in overlap
patients. Although these patients appear to have a milder course
of the disease with a mean mRSS similar to lcSSc patients, but
less lung ﬁbrosis and heart involvement, when compared to
dcSSc patients, they progressed more rapidly with earlier and
more widespread signiﬁcant organ involvement than patients
with lcSSc. This study demonstrates that patients with
SSc-overlap, on average, carry a higher disease burden than
patients with the limited form.
Based on a large cohort, this study strongly supports the idea
that patients with SSc-overlap syndromes should be regarded as
a separate subset of patients with SSc.
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